EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rethinking oral bioavailability in drug discovery: lessons from metformin, berberine, and intestinal mitochondrial complex I

Liang Le, Baoping Jiang

Acta Materia Medica · 2026 · 5 (2)

DOI: 10.15212/amm-2026-0051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Materia Medica, 2026. Verfasst von Liang Le und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poor oral bioavailability is often viewed as a barrier to the development of medicines from traditional and indigenous pharmacopeias. Berberine, a major alkaloid of Coptidis Rhizoma, challenges this assumption because it shows glucose-lowering activity despite limited systemic exposure. This commentary examines whether intestinally restricted mitochondrial and metabolic actions may represent a development opportunity. Recent intestine-specific NDI1 experiments demonstrated that inhibition of mitochondrial complex I in the intestinal epithelium contributes to the acute glucose-lowering effects of oral metformin and berberine in mice. These findings align with earlier observations that metformin enhances intestinal glucose uptake, glycolysis, lactate production, and gut-derived metabolic signaling, and provide a mechanistic framework for the local actions, microbial conversion, and poor absorption of berberine. For selected ethnomedicine-derived compounds, therapeutic development might optimize exposure at the site required for efficacy rather than maximize plasma bioavailability. Nevertheless, intestinal complex I is a predominantly preclinical antidiabetic target, and citrulline remains a candidate pharmacodynamic biomarker rather than a validated measure of target engagement. Quantitative comparisons must retain the species, dose, sampling compartment, and assay context; lower systemic exposure is not, by itself, evidence of superior efficacy or safety.

Zitieren

APA

Le, L., & Jiang, B. (2026). Rethinking oral bioavailability in drug discovery: lessons from metformin, berberine, and intestinal mitochondrial complex I. Acta Materia Medica, 5(2). https://doi.org/10.15212/amm-2026-0051

Vancouver

Le L, Jiang B. Rethinking oral bioavailability in drug discovery: lessons from metformin, berberine, and intestinal mitochondrial complex I. Acta Materia Medica. 2026;5(2). doi:10.15212/amm-2026-0051

BibTeX
@article{Le2026,
  author = {Le, Liang and Jiang, Baoping},
  title = {Rethinking oral bioavailability in drug discovery: lessons from metformin, berberine, and intestinal mitochondrial complex I},
  journal = {Acta Materia Medica},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.15212/amm-2026-0051}
}
Kostenlos starten →